Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD, an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia.

Built in collaboration with clinical experts and Level Ex, “the world’s leading medical video game studio,” DISCOVER TD uses gameplay, artistry, and cutting-edge technology to bring patient visits to life in realistic detail. Each avatar presents various manifestations of tardive dyskinesia (TD) or other drug-induced movement disorders and is complete with a unique patient history. Users can pose questions, screen, diagnose and determine appropriate management plans by interacting with virtual patients.

DISCOVER TD, which was recently named the PM360 Trailblazer Award 2023 Gold Winner, can be accessed at for healthcare providers to use any time from any device with Internet access. It can also be used to train students and residents.

“An interactive tool can help healthcare providers who may be less experienced in diagnosing and managing TD practice patient interactions to help identify the condition,” said Mercedes Perez-Rodriguez, M.D., Ph.D., Associate Professor of Psychiatry and Associate Training Director for Research at the Icahn School of Medicine at Mount Sinai. “In addition to the patient history, the key to differential diagnosis is knowing what the characteristic movements of different drug-induced movement disorders look like, and this tool helps users distinguish these movements through a simulated physical exam so that they can make a proper diagnosis and management plan.”

“TD can be a significant burden for patients already managing an underlying mental illness,” said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. “It’s our hope that this new educational tool will further empower healthcare professionals to confidently recognize, diagnose and appropriately manage TD, which can have a positive impact for patients.”

The tool will be available for demonstration at the Neurocrine Medical booth at the 2023 NEI Congress, November 9–12 in Colorado Springs, Colo.

View more information about DISCOVER TD at

Dr. Mercedes Perez-Rodriguez is a paid consultant for Neurocrine Biosciences, Inc.


Leave a Reply

Your email address will not be published. Required fields are marked *